An update on the toxicity of Aβ in Alzheimer's disease

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 6, 2008, Pages 1033-1042

  Götz, Jürgen ^a   Ittner, Lars M ^a   Schonrock, Nicole ^a   Cappai, Roberto ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Amyloid; Mitochondria; Oligomer; Proteomic; Tau; Transgenic

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALPHA SECRETASE; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BETA SECRETASE; GAMMA SECRETASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TAU PROTEIN; TRANSCRIPTION FACTOR YY1;

ALZHEIMER DISEASE; CLINICAL FEATURE; DISEASE COURSE; FRONTOTEMPORAL DEMENTIA; FUNCTIONAL GENOMICS; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; LONG TERM POTENTIATION; MOLECULAR INTERACTION; NERVE CELL DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PROTEIN AGGREGATION; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION;

EID: 60249086597     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s3016     Document Type: Review

References (137)

1. Abramov AY, Canevari L, Duchen MR. 2004. Calcium signals induced by amyloid beta peptide and their consequences in neurons and astrocytes in culture. Biochim Biophys Acta, 1742:81-7.
2. Ambroggio EE, Kim DH, Separovic F, et al. 2005. Surface behavior and lipid interaction of Alzheimer beta-amyloid peptide 1-42: a membrane-disrupting peptide. Biophys J, 88:2706-13.
3. Anandatheerthavarada HK, Biswas G, Robin MA, et al. 2003. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol, 161:41-54.
4. Arancio O, Zhang HP, Chen X, et al. 2004. RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice. Embo J, 23:4096-105.
5. Arendt T. 2003. Synaptic plasticity and cell cycle activation in neurons are alternative effector pathways: the 'Dr Jekyll and Mr. Hyde concept' of Alzheimer's disease or the yin and yang of neuroplasticity. Prog Neurobiol, 71:83-248.
6. Arispe N, Rojas E, Pollard HB. 1993. Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum. Proc Natl Acad Sci U S A, 90:567-71.
7. Arnold SE, Hyman BT, Flory J, et al. 1991. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex, 1:103-16.
8. Baker M, Mackenzie IR, Pickering-Brown SM, et al. 2006. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 442:916-9.
9. Barghorn S, Nimmrich V, Striebinger A, et al. 2005. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J Neurochem, 95:834-47.
10. Bhatia R, Lin H, Lal R. 2000. Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. Faseb J, 14:1233-43.
11. Bi X, Gall CM, Zhou J, et al. 2002. Uptake and pathogenic effects ofamyloid beta peptide 1-42 are enhanced by integrin antagonists and blocked by NMDA receptor antagonists. Neuroscience, 112:827-40.
12. Bolmont T, Clavaguera F, Meyer-Luehmann M, et al. 2007. Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP × Tau transgenic mice. Am J Pathol, 171:2012-20.
13. Braak H, and Braak E. 199 I. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl), 82:239-59.
14. Braak H, Braak E. 1995. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging, 16:271-8; discussion 8-84.
15. Braithwaite SP, Paul S, Nairn AC, et al. 2006. Synaptic plasticity: one STEP at a time. Trends Neurosci, 29:452-8.
16. Cappai R, and Bamham KJ. 2008. Delineating the mechanism of Alzheimer's disease A beta peptide neurotoxicity. Neurochem Res, 33:526-32.
17. Casas C, Sergeant N, Itier JM, et al. 2004. Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol, 165:1289-300.
18. Caspersen C, Wang N, Yao J, et al. 2005. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. Faseb J, 19:2040-1.
19. Chen F, David D, Ferrari A, et al. 2004a. Posttranslational modifications of tau - Role in human tauopathies and modeling in transgenic animals. Curr Drug Targets, 5:503-15.
20. Chen F, Wollmer MA, Hoerndli F, et al. 2004b. Role for glyoxalase I in Alzheimer's disease. Proc Natl Acad Sci U S A, 101:7687-92.
21. Chin J, Palop JJ, Yu GQ, et al. 2004. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci, 24:4692-7.
22. Chong YH, Shin YJ, Lee EO, et al. 2006. ERK1/2 activation mediates Abeta oligomer-induced neurotoxicity via caspase-3 activation and tau cleavage in rat organotypic hippocampal slice cultures. J Biol Chem, 281:20315-25.
23. Cleary JP, Walsh DM, Hofmeister JJ, et al. 2005. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci, 8:79-84.
24. Coulson EJ 2006. Does the p 75 neurotrophin receptor mediate Abeta-induced toxicity in Alzheimer's disease? J Neurochem, 98:654-60.
25. Crouch PJ, Blake R, Duce JA, et al. 2005. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta 1-42. J Neurosci, 25:672-9.
26. Cruts M, Gijselinck I, van der Zee J, et al. 2006. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature, 442:920-4.
27. David D, Hoerndli F, Gotz J. 2005a. Functional Genomics meets neurodegenerative disorders Part I: Transcriptomic and proteomic technology. Prog Neurobiol, 76:153-68.
28. David DC, Hauptmann S, Scherping I, et al. 2005b. Proteomic and functional analysis reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem, 280:23802-14.
29. David DC, Ittner LM, Gehrig P, et al. 2006. β-Amyloid treatment of two complementary P301L tau-expressing Alzheimer's disease models reveals similar deregulated cellular processes. Proteomics, 6:6566-77.
30. De Felice FG, Velasco PT, Lambert MP, et al. 2007. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem, 282:11590-601.
31. Deane R, Wu Z, Sagare A, et al. 2004. LRP/amyloid beta-peptide interaction mediates differential brain efflux ofAbeta isoforms. Neuron, 43:333-44.
32. Delacourte A, Sergeant N, Champain D, et al. 2002. Nonoverlapping but synergetie tau and APP pathologies in sporadic Alzheimer's disease. Neurology, 59:398-407.
33. Demuro A, Mina E, Kayed R, et al. 2005. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem, 280:17294-300.
34. Deters N, Ittner LM, and Gotz J. 2008. Divergent phosphorylation pattern of tau in P301L tau transgenic mice. Eur J Neurosci, 28:137-47.
35. Devi L, Prabhu BM, Galati DF, et al. 2006. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci, 26:9057-68.
36. 42) both impair mitochondrial function in P301L tau transgenic mice. J Mol Med, 86:1255-67.
37. Eckert A, Hauptmann S, Scherping I, et al. 2008b. Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenie mice. Neurodegener Dis, 5:157-9.
38. Edbauer D, Winkler E, Regula JT, et al. 2003. Reconstitution of gamma-secretase activity. Nat Cell Biol, 5:486-8.
39. Ferrari A, Hoerndli F, Baechi T, et al. 2003. Beta-amyloid induces PHF-like tau filaments in tissue culture. J Biol Chem, 278:40162-8.
40. Games D, Adams D, Alessandrini R, et al. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein [see comments]. Nature, 373:523-7.
41. Glenner GG, and Wong CW. 1984. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun, 120:885-90.
42. Goedert M, Wischik CM, Crowther RA, et al. 1988. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A, 85:4051-5.
43. Gomez-Ramos P, and Asuneion Moran M. 2007. Ultrastructural localization of intraneuronal Abeta-peptide in Alzheimer disease brains. J Alzheimers Dis, 11:53-9.
44. Gotz J 2001. Tau and transgenic animal models. Brain Res Brain Res Rev, 35:266-86.
45. Gotz J, Chen F, Barmettler R, et al. 2001a. Tau filament formation in transgenic mice expressing P301L Tan. J Biol Chem, 276:529-34.
46. Gotz J, Chen F, van Dorpe J, et al. 2001b. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Abeta42 fibrils. Science, 293:1491-5.
47. Gotz J, Deters N, Doldissen A, et al. 2007. A decade of tau transgenic animal models and beyond. Brain Pathol, 17:91-103.
48. Gotz J, and Ittner LM. 2008. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci, 9:532-44.
49. Gotz J, Ittner LM, Fandrich M, et al. 2008. Is tau aggregation toxic or protective: a sensible question in the absence of sensitive methods? J A lzheimers Dis, 14:423-9.
50. Gotz J, Ittner LM, Kins S. 2006. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease? J Neurochem, 98:993-1006.
51. Gotz J, and Nitsch RM. 2001. Compartmentalized tau hyperphosphorylation and increased levels of kinases in transgenic mice. Neuroreport, 12:2007-16.
52. Gotz J, Probst A, Spillantini MG, et al. 1995. Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. Embo J, 14:1304-13.
53. Gotz J, Schild A, Hoerndli F, et al. 2004a. Amyloid-induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissue-culture models. Int J Dev Neurosci, 22:453-65.
54. Gotz J, Streffer JR, David D, et al. 2004b. Transgenic animal models of Alzheimer's disease and related disorders: Histopathology, behavior and therapy. Mol Psychiatry, 9:664-83.
55. Gotz J, Tolnay M, Barmettler R, et al. 2001 e. Oligodendroglial tau filament formation in transgenic mice expressing G272V tau. Eur J Neurosci, 13:2131-40.
56. Graff-Radford NR, Woodruff BK. 2007. Frontotemporal dementia. Semin Neurol, 27:48-57.
57. Habicht G, Haupt C, Friedrich RP, et al. 2007. Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing Abeta protofibrils. Proc Natl Acad Sci U S A, 104:19232-7.
58. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 297:353-6.
59. Harper JD, and Lansbury PT, Jr. 1997. Models of amyloid seeding in Alzheimer's disease and serapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem, 66:385-407.
60. Hartley DM, Walsh DM, Ye CP, et al. 1999. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci, 19:8876-84.
61. Hoerndli F, David D, Gotz J. 2005. Functional genomics meets neurodegenerative disorders. Part II: Application and data integration. Prog Neurobiol, 76:169-88.
62. Hoerndli FJ, Pelech S, Papassotiropoulos A, et al. 2007. Abeta treatment and P301L tau exPression in an Alzheimer's disease tissue culture model act synergistically to promote aberrant cell cycle re-entry. Eur J Neurosci, 26:60-72.
63. Hoerndli FJ, Toigo M, Schild A, et al. 2004. Reference genes identified in SH-SY5Y cells using custom-made gene arrays with validation by quantitative polymerase chain reaction. Anal Biochem, 335:30-41.
64. Holscher C. 1998. Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol Dis, 5:129-41.
65. Hortschansky P, Schroeckh V, Christopeit T, et al. 2005. The aggregation kinetics of Alzheimer's beta-amyloid peptide is controlled by stochastic nucleation. Protein Sci, 14:1753-9.
66. Hsiao K, Chapman P, Nilsen S, et al. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice [see comments]. Science, 274:99-102.
67. Hutton M, Lendon CL, Rizzu P, et al. 1998. Association of missense and 5'-splice-site mutations in tan with the inherited dementia FTDP-17. Nature, 393:702-5.
68. Ishihara T, Hong M, Zhang B, et al. 1999. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the - human tau isoform. Neuron, 24:751-62.
69. Ittner LM, Fath T, Ke YD, et al. 2008. Parkinsonism and impaired axonal transport in a mouse model of frontotemporal dementia. Proc Natl Acad Sci U S A, 105:15997-16002.
70. Ivins KJ, Bui ET, Cotman CW. 1998. Beta-amyloid induces local neurite degeneration in cultured hippocampal neurons: evidence for neuritic apoptosis. Neurobiol Dis, 5:365-78.
71. Janus C, Pearson J, McLaurin J, et al. 2000. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 408:979-82.
72. Jicha GA, Bowser R, Kazam IG, et al. 1997. Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res, 48:128-32.
73. Keil U, Bonert A, Marques CA, et al. 2004. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem, 279:50310-20.
74. Kins S, Crameri A, Evans DR, et al. 200l. Reduced PP2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J Biol Chem, 276:38193-200.
75. Kins S, Kurosinski P, Nitsch RM, et al. 2003. Activation of the ERK and JNK signaling pathways caused by neuron specific inhibition of PP2A in transgenic mice. Am J Pathol, 163:833-43.
76. Klyubin I, Walsh DM, Lemere CA, et al. 2005. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med, 11:556-61.
77. Kulic L, Kurosinski P, Chen F, et al. 2006. Active immunization trial in Abeta42-injected P301L tau transgenic mice. Neurobiol Dis, 22:50-6.
78. Kurosinski P, Gotz J. 2002. Glial cells under physiologic and pathological conditions. Arch Neurol, 59:1524-8.
79. Lambert MP, Barlow AK, Chromy BA, et al. 1998. Diffusible, nonfibrillar ligands derived from Abeta-1 -42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A, 95:6448-53.
80. Lau TL, Ambroggio EE, Tew D J, et al. 2006. Amyloid-beta peptide disruption of lipid membranes and the effect of metal ions. J Mol Biol, 356:759-70.
81. Lee G, Newman ST, Gard DL, et al. 1998. Tan interacts with src-family non-receptor tyrosine kinases. J Cell Sci, 111:3167-77.
82. Lee VM, Goedert M, Trojanowski JQ. 2001. Neurodegenerative tauopathies. Annu Rev Neurosci, 24:1121-59.
83. Lesne S, Koh MT, Kotilinek L, et al. 2006. A specific amyloid-beta protein assembly in the brain impairs memory. Nature, 440:352-7.
84. Lewis J, Dickson DW, Lin W-L, et al. 2001. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant Tau and APP. Science, 293:1487-91.
85. Lim YA, Ittner LM, Lim YL, et al. 2008. Human but not rat amylin shares neurotoxic properties with Abeta42 in long-term hippocampal and cortical cultures. FEBS Lett, 582:2188-94.
86. Lin H, Bhatia R, Lal R. 2001. Amyloid beta protein forms ion channels: implications for Alzheimer's disease pathophysiology. Faseb J, 15:2433-44.
87. Lustbader JW, Cirilli M, Lin C, et al. 2004. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science, 304:448-52.
88. Manczak M, Anekonda TS, Henson E, et al. 2006. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet, 15:1437-49.
89. Masters CL, Simms G, Weinman NA, et al. 1985. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A, 82:4245-9.
90. Minogue AM, Schmid AW, Fogarty MP, et al. 2003. Activation of the c-Jun N-terminal kinase signaling cascade mediates the effect of amyloid-beta on long term potentiation and cell death in hippocampus: a role for interleukin- 1beta? J Biol Chem, 278:27971-80.
91. Mucke L, Masliah E, Yu GQ, et al. 2000. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci, 20:4050-8.
92. Necula M, Kayed R, Milton S, et al. 2007. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem, 282:10311-24.
93. Neumann M, Mackenzie IR, Cairns N J, et al. 2007. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol, 66:152-7.
94. Neumann M, Sampatbu DM, Kwong LK, et al. 2006. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314:130-3.
95. Patel V, Araya R, Chatterjee S, et al. 2007. Treatment and prevention of mental disorders in low-income and middle-income countries. Lancet, 370:991-1005.
96. Pellarin R, Caflisch A. 2006. Interpreting the aggregation kinetics of amyloid peptides. J Mol Biol, 360:882-92.
97. Pennanen L, Gotz J. 2005. Different tau epitopes define Abeta(42)-mediated tau insolubility. Biochem Biophys Res Coramun, 337:1097-101.
98. Pennanen L, Welzl H, D'Adamo P, et al. 2004. Accelerated extinction of conditioned taste aversion in P301L tau transgenic mice. Neurobiol Dis, 15:500-9.
99. Pennanen L, Wolfer DP, Nitsch RIM, et al. 2006. Impaired spatial reference memory and increased exploratory behavior in P301L tau transgenic mice. Genes Brain Behav, 5:369-79.
100. Perini G, Della-Bianca V, Politi V, et al. 2002. Role ofp 75 neurotrophin receptor in the neurotoxicity by beta-amyloid peptides and synergistic effect of inflammatory cytokines. J Exp Med, 195:907-18.
101. Pike C J, Burdick D, Walencewicz AJ, et al. 1993. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci, 13:1676-87.
102. Pike CJ, Walencewicz AJ, Glabe CG, et al. 1991a. Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur J Pharmacol, 207:367-8.
103. Pike CJ, Walencewicz AJ, Glabe CG, et al. 1991b. In vitro aging of beta-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res, 563:311-4.
104. Pollard HB, Arispe N, Roj as E. 1995. Ion channel hypothesis for Alzheimer amyloid peptide neurotoxicity. Cell Mol Neurobiol, 15:513-26.
105. Poorkaj P, Bird TD, Wijsman E, et al. 1998. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol, 43:815-25.
106. Probst A, Gotz J, Wiederhold KH, et al. 2000. Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol (Berl), 99:469-81.
107. Rapoport M, Dawson HN, Binder LI, et al. 2002. Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A, 99:6364-9.
108. Roberson ED, Scearce-Levie K, Palop J J, et al. 2007. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science, 316:750-4.
109. Rocchi A, Pellegrini S, Siciliano G, et al. 2003. Causative and susceptibility genes for Alzheimer's disease: a review. Brain Res Bull, 61:1-24.
110. Selkoe DJ. 2002. Alzheimer's disease is a synaptic failure. Science, 298: 789 91.
111. Shibata M, Yamada S, Kumar SR, et al. 2000. Clearance of Alzheimer's amyloid-beta(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest, 106:1489-99.
112. Small DH, Mok SS, Bornstein JC. 2001. OPINION Alzheimer's disease and Abeta toxicity: from top to bottom. Nat Rev Neurosci, 2:595-8.
113. Smith DP, Ciccotosto GD, Tew DJ, et al. 2007. Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-beta peptide. Biochemistry, 46:2881-91.
114. Snowden JS, Bathgate D, Varma A, et al. 2001. Distinct behavioural profiles in frontotemporal dementia and semantic dementia. J Neurol Neurosurg Psychiatry, 70:323-32.
115. Snyder EM, Nong Y, Almeida CG, et al. 2005. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci, 8:1051-8.
116. Sotthibundhu A, Sykes AM, Fox B, et al. 2008. Beta-amyloid (1-42) induces neuronal death through the p 75 neurotrophin receptor. J Neurosci, 28:3941-6.
117. Spillantini MG, Murrell JR, Goedert M, et al. 1998. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A, 95:7737-41.
118. Spittaels K, Van den Haute C, Van Dorpe J, et al. 1999. Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol, 155:2153-65.
119. Stalder M, Phinney A, Probst A, et al. 1999. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol, 154:1673-84.
120. Stine WB, Jr., Dahlgren KN, Krafft GA, et al. 2003. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem, 278:11612-22.
121. Sturchler-Pierrat C, Abramowski D, Duke M, et al. 1997. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A, 94:13287-92.
122. Takuma K, Yao J, Huang J, et al. 2005. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. Faseb J, 19:597-8.
123. Trommer BL, Shah C, Yun SH, et al. 2005. ApoE isoform-specific effects. on LTP: blockade by oligomeric amyloid-beta1-42. Neurobiol Dis, 18:75-82.
124. Vassar R, Bennett BD, Babu-Khan S, et al. 1999. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science, 286:735-41.
125. Verdier Y, Zarandi M, Penke B. 2004. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J Pept Sci, 10:229-48.
126. Walsh DM, Klyubin I, Fadeeva JV, et al. 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 416:535-9.
127. Walsh DM, Klyubin I, Shankar GM, et al. 2005. The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention. Biockem Soc Trans, 33:1087-90.
128. Wang Q, Walsh DM, Rowan M J, et al. 2004. Block of long-term potentiation by naturally secreted and synthetic amyloid beta-peptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p 38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci, 24:3370-8.
129. Weder ND, Aziz R, Wilkins K, et al. 2007. Frontotemporal dementias: a review. Ann Gen Psychiatry, 6:15.
130. Wegiel J, Kuchna I, Nowicki K, et al. 2007. Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. Acta Neuropathol, 113:389-402.
131. White AR, Guirguis R, Brazier MW, et al. 2001. Sublethal concentrations of prion peptide PrP106-126 or the amyloid beta peptide of Alzheimer's disease activates expression ofproapoptotic markers in primary cortical neurons. Neurobiol Dis, 8:299-316.
132. White JA, Manelli AM, Holmberg KH, et al. 2005. Differential effects of oligomeric and fibrillar amyloid-beta 1-42 on astrocyte-mediated inflammation. Neurobiol Dis, 18:459-65.
133. Yan SD, Chen X, Fu J, et al. 1996. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature, 382:685-91.
134. Yan Y, Liu Y, Sorci M, et al. 2007. Surface plasmon resonance and nuclear magnetic resonance studies of ABAD-Abeta interaction. Biochemistry, 46:1724-31.
135. Yah Y, and Wang C. 2007. Abeta40 protects non-toxic Abeta42 monomer from aggregation. J Mol Biol, 369:909-16.
136. Yankner BA, Duffy LK, Kirschner DA. 1990. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science, 250:279-82.
137. Zhang Y, Hong Y, Bounhar Y, et al. 2003. p 75 neurotrophin receptor protects primary cultures of human neurons against extracellular amyloid beta peptide cytotoxicity. J Neurosci, 23:7385-94.